OBJECTIVE: To examine trends in bladder cancer survival among whites, blacks, Hispanics, and Asian/Pacific Islanders in the United States over a 30-year period. Racial disparities in bladder cancer outcomes have been documented with poorer survival observed among blacks. Bladder cancer outcomes in other ethnic minority groups are less well described. METHODS: From the Surveillance, Epidemiology and End Results cancer registry data, we identified patients diagnosed with transitional cell carcinoma of the bladder between 1975 and 2005. This cohort included 163,973 white, 7731 black, 7364 Hispanic, and 5934 Asian/Pacific Islander patients. We assessed the relationship between ethnicity and patient characteristics. Disease-specific 5-year survival was estimated for each ethnic group and for subgroups of stage and grade. RESULTS: Blacks presented with higher-stage disease than whites, Hispanics, and Asian/Pacific Islanders, although a trend toward earlier-stage presentation was observed in all groups over time. Five-year disease-specific survival was consistently worse for blacks than for other ethnic groups, even when stratified by stage and grade. Five-year disease-specific survival was 82.8% in whites compared with 70.2% in blacks, 80.7% in Hispanics, and 81.9% in Asian/Pacific Islanders. There was a persistent disease-specific survival disadvantage in black patients over time that was not seen in the other ethnic groups. CONCLUSION: Ethnic disparities in bladder cancer survival persist between whites and blacks, whereas survival in other ethnic minority groups appears similar to that of whites. Further study of access to care, quality of care, and treatment decision making among black patients is needed to better understand these disparities.
OBJECTIVE: To examine trends in bladder cancer survival among whites, blacks, Hispanics, and Asian/Pacific Islanders in the United States over a 30-year period. Racial disparities in bladder cancer outcomes have been documented with poorer survival observed among blacks. Bladder cancer outcomes in other ethnic minority groups are less well described. METHODS: From the Surveillance, Epidemiology and End Results cancer registry data, we identified patients diagnosed with transitional cell carcinoma of the bladder between 1975 and 2005. This cohort included 163,973 white, 7731 black, 7364 Hispanic, and 5934 Asian/Pacific Islander patients. We assessed the relationship between ethnicity and patient characteristics. Disease-specific 5-year survival was estimated for each ethnic group and for subgroups of stage and grade. RESULTS: Blacks presented with higher-stage disease than whites, Hispanics, and Asian/Pacific Islanders, although a trend toward earlier-stage presentation was observed in all groups over time. Five-year disease-specific survival was consistently worse for blacks than for other ethnic groups, even when stratified by stage and grade. Five-year disease-specific survival was 82.8% in whites compared with 70.2% in blacks, 80.7% in Hispanics, and 81.9% in Asian/Pacific Islanders. There was a persistent disease-specific survival disadvantage in black patients over time that was not seen in the other ethnic groups. CONCLUSION: Ethnic disparities in bladder cancer survival persist between whites and blacks, whereas survival in other ethnic minority groups appears similar to that of whites. Further study of access to care, quality of care, and treatment decision making among black patients is needed to better understand these disparities.
Authors: G R Prout; M N Wesley; R S Greenberg; V W Chen; C C Brown; A W Miller; R S Weinstein; S J Robboy; M A Haynes; R S Blacklow; B K Edwards Journal: Cancer Date: 2000-09-15 Impact factor: 6.860
Authors: George R Prout; Margaret N Wesley; Peter G McCarron; Vivien W Chen; Raymond S Greenberg; Robert M Mayberry; Brenda K Edwards Journal: Cancer Date: 2004-02-01 Impact factor: 6.860
Authors: Jill K Schinkel; Stephanie Shao; Shelia H Zahm; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu Journal: Cancer Epidemiol Date: 2016-05-06 Impact factor: 2.984
Authors: Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: Sanaz Ghafouri; Aaron Burkenroad; Morgan Pantuck; Bara Almomani; Dimitris Stefanoudakis; John Shen; Alexandra Drakaki Journal: World J Urol Date: 2020-05-02 Impact factor: 4.226
Authors: Daniel A Barocas; Joann Alvarez; Tatsuki Koyama; Christopher B Anderson; Darryl T Gray; Jay H Fowke; Chaochen You; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson Journal: Cancer Date: 2013-12-11 Impact factor: 6.860
Authors: Emanuele Zaffuto; Marco Bandini; Stéphanie Gazdovich; Anne-Sophie Valiquette; Sami-Ramzi Leyh-Bannurah; Zhe Tian; Paolo Dell'Oglio; Markus Graefen; Marco Moschini; Andrea Necchi; Shahrokh F Shariat; Alberto Briganti; Francesco Montorsi; Pierre I Karakiewicz Journal: World J Urol Date: 2018-04-27 Impact factor: 4.226
Authors: J Kellogg Parsons; John P Pierce; Loki Natarajan; Vicky A Newman; Leslie Barbier; James Mohler; Cheryl L Rock; Dennis D Heath; Khurshid Guru; Michael B Jameson; Hongying Li; Hossein Mirheydar; Michael A Holmes; James Marshall Journal: Cancer Prev Res (Phila) Date: 2013-07-18